Gapping down
In reaction to disappointing earnings/guidance: NDLS -15.5%, (Noodles & Co announces management and Board changes, sees Q2 revs below consensus), SANM -9.9%, FCX -6.7%, EFII -4.4%, ORAN -4.2%, GILD -4.1%, MPWR -3.6%,CE -3.6%, GIG -3.3%, CDNS -3%, MCD -3%, BP -2.2%, BLX -1.7%, SPN -1.6%, CMP -1.5%, MMM -1.5%, VNOM -1.3%, (Viper Energy Partners announces a 7 mln common unit underwritten public offering), VZ -0.9%, CAT -0.9%, CVLT -0.8%,KEY -0.7%, JBLU -0.5%, MDXG -0.5%
M&A news: KLDX -3.4% ( to acquire the Hollister mine and the Esmeralda mine and ore milling complex located in Northern Nevada; discloses CAD $100 mln bought deal financing)
Select oil/gas related names showing early weakness: CHK -2.5%, MRO -1.9%, WLL -1.9%, RDS.A -0.6%
Other news:
In reaction to disappointing earnings/guidance: NDLS -15.5%, (Noodles & Co announces management and Board changes, sees Q2 revs below consensus), SANM -9.9%, FCX -6.7%, EFII -4.4%, ORAN -4.2%, GILD -4.1%, MPWR -3.6%,CE -3.6%, GIG -3.3%, CDNS -3%, MCD -3%, BP -2.2%, BLX -1.7%, SPN -1.6%, CMP -1.5%, MMM -1.5%, VNOM -1.3%, (Viper Energy Partners announces a 7 mln common unit underwritten public offering), VZ -0.9%, CAT -0.9%, CVLT -0.8%,KEY -0.7%, JBLU -0.5%, MDXG -0.5%
M&A news: KLDX -3.4% ( to acquire the Hollister mine and the Esmeralda mine and ore milling complex located in Northern Nevada; discloses CAD $100 mln bought deal financing)
Select oil/gas related names showing early weakness: CHK -2.5%, MRO -1.9%, WLL -1.9%, RDS.A -0.6%
Other news:
- TKAI -67.9% (announces clinical update; co to discontinue Phase 3 ARMOR3-SV trial of Galeterone in AR-V7 Positive mCRPC)
- CRME -34.9% (announces proposed underwritten public offering of common stock)
- MSTX -21.3% (Mast Therapeutics provides guidance on the anticipated timing for announcement of top-line data from the EPIC study, provided guidance on the anticipated timing for announcement of top-line data from the EPIC study)
- SDLP -11.9% (reduces quarterly distribution to $0.10 per unit (from $0.25 per unit prior))
- TCAP -4.7% (commences 6.25 mln common stock offering)
- PRKR -3.3% ( files for ~1.44 mln share common stock offering by selling shareholders)
- CELG -3.2% (announces the Lymphoma Academic Research Organisation reported initial data from a phase III REMARC clinical study; REMARC achieved the primary endpoint of a statistically significant improvement inPFS for patients receiving REVLIMID)
Analyst comments:
- SC -2.2% (downgraded to Equal Weight from Overweight at Barclays)
- WFM -2.2% (downgraded to Sell from Neutral at Goldman )
- CMG -1.9% (downgraded to Sell at Stifel)
- PNRA -1.4% (downgraded to Sell at Stifel)